LEADER 03855nam 2200853z- 450 001 9910557390503321 005 20231214133456.0 035 $a(CKB)5400000000041993 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77077 035 $a(EXLCZ)995400000000041993 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMultimodality Treatments in Metastatic Gastric Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (162 p.) 311 $a3-0365-2592-0 311 $a3-0365-2593-9 330 $aGastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics. 606 $aMedicine$2bicssc 610 $aadvanced gastric cancer 610 $aprecision medicine 610 $anew drug development 610 $agastro-oesophageal cancer 610 $amutational concordance 610 $aexome sequencing 610 $aformalin fixed paraffin embedded 610 $abiomarkers 610 $agastric cancer 610 $ametastatic 610 $abody composition 610 $asarcopenia 610 $avisceral fat area 610 $asubcutaneous fat area 610 $aoutcome 610 $atoxicity 610 $aliver metastasis 610 $aconversion surgery 610 $ahepatectomy 610 $astage iv gastric cancer 610 $aimmune checkpoint inhibitors 610 $aEpstein Barr Virus 610 $atumor mutational burden 610 $amicrosatellite instability 610 $apredictive biomarkers 610 $aCAR T cell therapy 610 $avaccines 610 $anutritional status 610 $ametastatic gastric cancer 610 $atarget therapy 610 $abone flare 610 $astage IV 610 $atreatment 610 $aRANK-L 610 $aliquid biopsy 610 $acirculating tumor cell 610 $acfDNA 610 $actDNA 610 $aepithelial-mesenchymal transition 610 $aresistance to treatment 610 $aHER2-inhibition 610 $aVEGFR-inhibition 610 $aimmunotherapy 610 $aresponse monitoring 615 7$aMedicine 700 $aPetrillo$b Angelica$4edt$01295530 702 $aPetrillo$b Angelica$4oth 906 $aBOOK 912 $a9910557390503321 996 $aMultimodality Treatments in Metastatic Gastric Cancer$93023583 997 $aUNINA